Yukiya Narita Selected Research

Bevacizumab (Avastin)

11/2023	Bevacizumab, Irinotecan, and Biweekly Trifluridine/Tipiracil for Metastatic Colorectal Cancer: MODURATE, a Phase Ib Study.
3/2023	Impact of omitting fluorouracil from FOLFIRI plus bevacizumab as second-line chemotherapy for patients with metastatic colorectal cancer.
1/2023	Differential Efficacy of Targeted Monoclonal Antibodies in Left-Sided Colon and Rectal Metastatic Cancers.
11/2020	Phase I Study of Alternate-Day Administration of S-1, Oral Leucovorin, and Bevacizumab for Refractory Metastatic Colorectal Cancer.
11/2018	Morphologic Response and Tumor Shrinkage as Early Predictive Markers in Unresectable Colorectal Liver Metastases.
1/2017	Efficacy of Second-Line Bevacizumab-Containing Chemotherapy for Patients with Metastatic Colorectal Cancer following First-Line Treatment with an Anti-Epidermal Growth Factor Receptor Antibody.
3/2016	A short interval between bevacizumab and anti-epithelial growth factor receptor therapy interferes with efficacy of subsequent anti-EGFR therapy for refractory colorectal cancer.
8/2015	A single-arm phase II trial of combined chemotherapy with S-1, oral leucovorin, and bevacizumab in heavily pre-treated patients with metastatic colorectal cancer.
2/2014	CA19-9 level as a prognostic and predictive factor of bevacizumab efficacy in metastatic colorectal cancer patients undergoing oxaliplatin-based chemotherapy.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Yukiya Narita Research Topics

Disease

25	Stomach Neoplasms (Stomach Cancer) 10/2023 - 08/2014
20	Neoplasms (Cancer) 10/2023 - 04/2015
16	Colorectal Neoplasms (Colorectal Cancer) 11/2023 - 02/2014
5	Adenocarcinoma 06/2023 - 01/2017
4	Disease Progression 01/2021 - 08/2017
4	Neoplasm Metastasis (Metastasis) 01/2021 - 12/2017
3	Neutropenia 11/2023 - 01/2017
3	Esophageal Squamous Cell Carcinoma 01/2023 - 08/2015
3	Esophageal Neoplasms (Esophageal Cancer) 01/2020 - 08/2015
2	Febrile Neutropenia 11/2023 - 01/2017
2	Hypertension (High Blood Pressure) 10/2022 - 01/2017
2	Ascites 01/2021 - 09/2017
2	Gastrointestinal Neoplasms (Gastrointestinal Cancer) 11/2020 - 01/2019
2	Mucositis 11/2020 - 08/2015
2	Diarrhea 11/2020 - 08/2015
2	Sarcopenia 10/2018 - 06/2017
2	Disseminated Intravascular Coagulation 09/2017 - 01/2017
2	Nausea 01/2017 - 09/2016
1	Squamous Cell Carcinoma of Head and Neck 03/2024
1	Nasopharyngeal Carcinoma 03/2024
1	Cachexia 10/2023
1	Colonic Neoplasms (Colon Cancer) 01/2023
1	Rectal Neoplasms (Rectal Cancer) 01/2023
1	Cholangitis 10/2022
1	Hyperlipidemias (Hyperlipidemia) 10/2022
1	Obstructive Jaundice (Cholestatic Jaundice) 10/2022
1	Microsatellite Instability 01/2021
1	Second Primary Neoplasms (Neoplasms, Second) 01/2020
1	Chronic Disease (Chronic Diseases) 01/2018
1	Hemangiosarcoma (Angiosarcoma) 09/2017
1	Brain Diseases (Brain Disorder) 06/2017
1	Thrombocytopenia (Thrombopenia) 01/2017
1	Leukopenia 01/2017
1	Multiple Endocrine Neoplasia Type 2a (MEN 2) 01/2017
1	Anemia 01/2017
1	Hand-Foot Syndrome 01/2017
1	Vomiting 09/2016
1	Peripheral Nervous System Diseases (PNS Diseases) 04/2015

Drug/Important Bio-Agent (IBA)

9	Bevacizumab (Avastin)FDA Link 11/2023 - 02/2014
8	Fluorouracil (Carac)FDA LinkGeneric 03/2024 - 04/2015
8	NivolumabIBA 10/2023 - 11/2018
7	Immune Checkpoint InhibitorsIBA 04/2023 - 01/2017
6	Cisplatin (Platino)FDA LinkGeneric 03/2024 - 08/2015
6	Irinotecan (Camptosar)FDA LinkGeneric 11/2023 - 09/2017
6	Oxaliplatin (Eloxatin)FDA LinkGeneric 11/2023 - 02/2014
6	Leucovorin (Folinic Acid)FDA Link 03/2023 - 04/2015
5	trifluridine tipiracil drug combinationIBA 11/2023 - 01/2017
4	taxaneIBA 07/2021 - 09/2017
3	Cetuximab (Erbitux)FDA Link 03/2024 - 03/2016
3	PlatinumIBA 01/2023 - 01/2017
3	RamucirumabIBA 07/2021 - 01/2019
3	Cytotoxins (Cytolysins)IBA 09/2020 - 08/2017
3	Trastuzumab (Herceptin)FDA Link 12/2018 - 08/2017
2	pembrolizumabIBA 03/2024 - 12/2021
2	Taxoids (Taxanes)IBA 06/2023 - 11/2018
2	Growth Factor ReceptorsIBA 01/2023 - 03/2016
2	ErbB Receptors (EGF Receptor)IBA 04/2021 - 01/2017
2	AntibodiesIBA 11/2018 - 01/2017
2	Biomarkers (Surrogate Marker)IBA 02/2018 - 01/2017
2	human ERBB2 proteinIBA 02/2018 - 08/2017
2	Dacarbazine (DIC)FDA LinkGeneric 09/2017 - 01/2017
2	Docetaxel (Taxotere)FDA Link 09/2017 - 08/2015
2	Aspartate Aminotransferases (Aspartate Transaminase)IBA 01/2017 - 01/2017
2	regorafenibIBA 01/2017 - 01/2017
1	B7-H1 AntigenIBA 03/2024
1	Gemcitabine FDA Link 03/2024
1	Niacin (Nicotinic Acid)FDA LinkGeneric 10/2023
1	CarbonIBA 10/2023
1	Vitamin B 6IBA 10/2023
1	EnzymesIBA 10/2023
1	Proteins (Proteins, Gene)FDA Link 10/2023
1	Glycine (Aminoacetic Acid)FDA LinkGeneric 10/2023
1	Vitamin B Complex (B Vitamins)IBA 10/2023
1	Monoclonal AntibodiesIBA 01/2023
1	Paclitaxel (Taxol)FDA LinkGeneric 09/2020
1	130-nm albumin-bound paclitaxelIBA 09/2017
1	Alanine Transaminase (SGPT)IBA 01/2017
1	BilirubinIBA 01/2017
1	Dexamethasone (Maxidex)FDA LinkGeneric 09/2016
1	Palonosetron (Aloxi)FDA Link 09/2016
1	Olanzapine (Zyprexa)FDA Link 09/2016
1	Panitumumab (Vectibix)FDA Link 03/2016
1	S-1 plus cisplatinIBA 08/2014
1	CarbohydratesIBA 02/2014
1	AntigensIBA 02/2014

Therapy/Procedure

30	Drug Therapy (Chemotherapy) 03/2024 - 02/2014
20	Therapeutics 03/2024 - 04/2015
5	Immunotherapy 04/2023 - 01/2017
2	Combination Drug Therapy (Combination Chemotherapy) 07/2021 - 08/2014
2	Drug Tapering 06/2017 - 08/2015
2	Neoadjuvant Therapy 10/2016 - 08/2015
2	Adjuvant Chemotherapy 08/2015 - 04/2015
1	Length of Stay 10/2022
1	Palliative Care (Palliative Therapy) 01/2021
1	Molecular Targeted Therapy 03/2017
1	Chemoradiotherapy 10/2016